ReviewDiscover oncology2026
The impact of m6A modified cargo conveyed by exosomes on the tumor microenvironment.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- EV-Mediated Oncogenic Regulation in Lung Cancer and Clinical Translation: From Liquid Biopsy to Targeted Delivery Systems.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The dynamic evolution of tumor microenvironment (TME) is the core of cancer progression. N6-methyladenosine (m6A) modification and exosome transport are key layers of post-transcriptional gene regulation and intercellular communication, respectively. However, the intersection of these two systems, namely the transportation of m6A modified bioactive cargoes through exosomes and reshaping of TME, still lacks systematic sorting. This review aims to fill this gap. Through systematic searches of PubMed, Scopus, and Web of Science, we identified 21 original preclinical studies focused on this area over the past five years. By analyzing these literature, a conceptual framework for the "m6A-exosome axis" was established for the first time, and how it mediates TME and its effects were elucidated. We found that bioactive molecules modified with m6A can be transported to TME through exosomes. During this process, these molecules can reshape existing stromal cells and immune cells, activate tumor associated cytokines, and regulate the malignant phenotype of tumor cells. This TME remodeling further affects pathological processes such as tumor angiogenesis, epithelial mesenchymal transition (EMT), immune escape, metastasis, and drug resistance. These findings indicate that the key components of this axis not only serve as potential biomarker candidates, but also represent a promising preclinical therapeutic target. Targeting this axis provides an innovative combination strategy framework for overcoming tumor growth and metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.